Maria Ann Fagan

Title: Maria Ann Fagan: Innovator in Pharmaceutical Chemistry

Introduction

Maria Ann Fagan is a notable inventor based in Basingstoke, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that act as serotonin and norepinephrine reuptake inhibitors. Her work has implications for the treatment of various mental health conditions.

Latest Patents

Maria Ann Fagan holds a patent for her invention titled "Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors." This patent describes a heretoaryloxy 3-substituted propanamine compound that includes specific structural features, such as the selection of A from —O— and —S—, and various substituents on phenyl and thienyl groups. The compound is designed to enhance the efficacy of treatments targeting serotonin and norepinephrine pathways.

Career Highlights

Maria is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. Her role involves research and development of innovative therapeutic solutions. With her expertise, she has contributed to advancing the understanding of pharmacological agents.

Collaborations

Throughout her career, Maria has collaborated with esteemed colleagues, including Peter Thaddeus Gallagher and Richard Edmund Rathmell. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Maria Ann Fagan's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in healthcare. Her patent and work at Eli Lilly and Company highlight her commitment to advancing medical science.